Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities

被引:100
|
作者
Venhorst, J
ter Laak, AM
Commandeur, JNM
Funae, Y
Hiroi, T
Vermeulen, NPE
机构
[1] Vrije Univ Amsterdam, Dept Pharmacochem, Fac Sci, Div Mol Toxicol,Leiden Amsterdam Ctr Drug Res, NL-1081 HV Amsterdam, Netherlands
[2] Osaka City Univ, Sch Med, Chem Lab, Abeno Ku, Osaka 545, Japan
关键词
D O I
10.1021/jm0209578
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The ligand-binding characteristics of rat and human CYP2D isoforms, i.e., rat CYP2D1-4 and human CYP2D6, were investigated by measuring IC50 values of 11 known CYP2D6 ligands using 7-methoxy-4-(aminomethyl)coumarin (MAMC) as substrate. Like CYP2D6, all rat CYP2D isozymes catalyzed the O-demethylation of MAMC with K-m and V-max values ranging between 78 and 145 muM and 0.048 and 1.122 min(-1), respectively. To rationalize observed differences in the experimentally determined IC50 values, homology models of the CYP2D isoforms were constructed. A homology model of CYP2D6 was generated on the basis of crystallized rabbit CYP2C5 and was validated on its ability to reproduce binding orientations corresponding to metabolic profiles of the substrates and to remain stable during unrestrained molecular dynamics simulations at 300 K Twenty-two active site residues, sharing up to 59% sequence identity, were identified in the CYP2D binding pockets and included CYP2D6 residues Phe120, Glu216, and Asp301. Electrostatic potential calculations displayed large differences in the negative charge of the CYP2D active sites, which was consistent with observed differences in absolute IC50 values. MD studies on the binding mode of sparteine, quinidine, and quinine in CYP2D2 and CYP2D6 furthermore concurred well with experimentally determined IC50 values and metabolic profiles. The current study thus provides new insights into differences in the active site topology of the investigated CYP2D isoforms.
引用
收藏
页码:74 / 86
页数:13
相关论文
共 50 条
  • [1] The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain
    Haduch, Anna
    Bromek, Ewa
    Daniel, Wladyslawa A.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 651 (1-3) : 51 - 58
  • [2] Chronic treatment with asenapine affects cytochrome P450 2D (CYP2D) in rat brain and liver. Pharmacological aspects
    Danek, Przemyslaw J.
    Bromek, Ewa
    Haduch, Anna
    Daniel, Wladyslawa A.
    NEUROCHEMISTRY INTERNATIONAL, 2021, 151
  • [3] Chronic treatment with iloperidone affects the cytochrome P450 2D (CYP2D) protein and activity in the brain and liver
    Danek, P. J.
    Daniel, W. A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S412 - S413
  • [4] Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters
    Haduch, Anna
    Bromek, Ewa
    Daniel, Wladyslawa A.
    PHARMACOLOGICAL REPORTS, 2013, 65 (06) : 1519 - 1528
  • [5] Functional Characterization of a First Avian Cytochrome P450 of the CYP2D Subfamily (CYP2D49)
    Cai, Hua
    Jiang, Jun
    Yang, Qi
    Chen, Qingmei
    Deng, Yiqun
    PLOS ONE, 2012, 7 (06):
  • [6] Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters
    Anna Haduch
    Ewa Bromek
    Władysława A. Daniel
    Pharmacological Reports, 2013, 65 : 1519 - 1528
  • [7] Progesterone oxidation by cytochrome P450 2D isoforms in the brain
    Hiroi, T
    Kishimoto, W
    Chow, T
    Imaoka, S
    Igarashi, TS
    Funae, Y
    ENDOCRINOLOGY, 2001, 142 (09) : 3901 - 3908
  • [8] Catalytic specificity of CYP2D isoforms in rat and human
    Hiroi, T
    Chow, T
    Imaoka, S
    Funae, Y
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (09) : 970 - 976
  • [9] The effect of ageing and cerebral serotonin deficit on the activity of cytochrome P450 2D (CYP2D) in the brain and liver of male rats
    Haduch, Anna
    Puklo, Renata
    Alenina, Natalia
    Nikiforuk, Agnieszka
    Popik, Piotr
    Bader, Michael
    Daniel, Wladyslawa A.
    NEUROCHEMISTRY INTERNATIONAL, 2020, 141
  • [10] The effect of chronic treatment with the asenap-ine on the cytochrome P450 2D (CYP2D) activity in different brain areas
    Danek, P.
    Daniel, W. A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 31 : S2 - S3